Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report

Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Takumi, Chieko, Tsuji, Taisuke, Hamashima, Ryosuke, Shiotsu, Shinsuke, Yuba, Tatsuya, Urata, Yoji, Hiraoka, Noriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/
https://www.ncbi.nlm.nih.gov/pubmed/29988633
http://dx.doi.org/10.1002/ccr3.1627
_version_ 1783336757301870592
author Yoshimura, Akihiro
Takumi, Chieko
Tsuji, Taisuke
Hamashima, Ryosuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Urata, Yoji
Hiraoka, Noriya
author_facet Yoshimura, Akihiro
Takumi, Chieko
Tsuji, Taisuke
Hamashima, Ryosuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Urata, Yoji
Hiraoka, Noriya
author_sort Yoshimura, Akihiro
collection PubMed
description Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.
format Online
Article
Text
id pubmed-6028417
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60284172018-07-09 Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report Yoshimura, Akihiro Takumi, Chieko Tsuji, Taisuke Hamashima, Ryosuke Shiotsu, Shinsuke Yuba, Tatsuya Urata, Yoji Hiraoka, Noriya Clin Case Rep Case Reports Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression. John Wiley and Sons Inc. 2018-05-29 /pmc/articles/PMC6028417/ /pubmed/29988633 http://dx.doi.org/10.1002/ccr3.1627 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Yoshimura, Akihiro
Takumi, Chieko
Tsuji, Taisuke
Hamashima, Ryosuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Urata, Yoji
Hiraoka, Noriya
Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title_full Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title_fullStr Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title_full_unstemmed Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title_short Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
title_sort pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/
https://www.ncbi.nlm.nih.gov/pubmed/29988633
http://dx.doi.org/10.1002/ccr3.1627
work_keys_str_mv AT yoshimuraakihiro pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT takumichieko pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT tsujitaisuke pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT hamashimaryosuke pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT shiotsushinsuke pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT yubatatsuya pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT uratayoji pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport
AT hiraokanoriya pulmonarypleomorphiccarcinomawithpseudoprogressionduringnivolumabtherapyandtheusefulnessoftumormarkersacasereport

Ejemplares similares